Advertisement

Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Non-insulin-dependent diabetes mellitus (NIDDM) is often characterized by an increase in VLDLtriglyceride, VLDL-cholesterol, LDL-cholesterol and a reduction in HDL-cholesterol. HMG-CoA reductase inhibitors significantly lower cholesterol rates and have an indirect effect on the LDL receptor. We measured the effect of simvastatin in 28 hypercholesterolemic subjects, including 14 with NIDDM in good metabolic control (HbAIc 7.8% ± 1.3%). A 24-week treatment with 10 mg/day (weeks 1–4), 20 mg/day (weeks 5–8) and 40 mg/day (weeks 9–24) simvastatin revealed different responses in diabetic and non-diabetic patients. Total cholesterol, LDL-cholesterol and apo B decreased significantly in both groups (less in the diabetics), whereas only NIDDM patients displayed a significant reduction in VLDL-cholesterol and VLDL-apo B. In the non-diabetics, the reduction in plasma cholesterol was mainly confined to the LDL fraction (276 ± 65 vs. 132 ± 28 mg/dl), whereas a significant fall in VLDL-cholesterol (45 ± 19 vs. 21 ± 10 mg/dl) was more evident in the NIDDM patients. Simvastatin also influenced plasma apo B levels (221 ± 33 vs 134 ± 23 mg/dl in non-diabetics and 182 ± 44 vs. 134 ± 30 mg/dl in diabetics). Significant reduction of apo B, LDL-apo B (205 ± 39 vs. 128 ± 23 mg/dl) in the non-diabetics and VLDL-apo B (16 ± 5 vs. 9 ± 2 mg/dl) in the diabetics, indicates that the VLDL are primarily concerned when statins are administered in NIDDM. Our data suggest that statins are also useful in the treatment of hypercholesterolernia in NIDDM to prevent the macroangiopathic complications often observed in this disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Howard B.
        Lipoprotein metabolism in diabetes mellitus.
        J. Lipid Res. 1987; 28: 613
        • Dunn F.L.
        • Raskin P.
        • Bilheimer D.W.
        • Grundy S.M.
        The effect of diabetic control on very low-density lipoprotein-triglyceride metabolism in patients with type II diabetes mellitus and marked hypertriglyceridemia.
        Metabolism. 1984; 33: 117
        • Kannel W.B.
        • McGee D.L.
        Diabetes and cardiovascular disease: the Framingham study.
        J. Am. Med. Assoc. 1979; 241: 2035
        • Bilheimer D.W.
        • Grundy S.M.
        • Brown M.S.
        • Goldstein J.L.
        Mevinolin and colestipol stimulate receptormediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
        in: Proc. Nad. Acad. Sci. USA. 80. 1983: 4124
        • Grundy S.M.
        • Vega G.L.
        Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
        J. Lipid Res. 1985; 26: 1464
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
        J. Clin. Invest. 1955; 34: 1345
        • Gidez L.I.
        • Miller G.J.
        • Burnstein M.
        • Slagle S.
        • Eder H.A.
        Separation and quantitation of human plasma high density lipoproteins by a simple precipitation procedure.
        J. Lipid Res. 1982; 23: 1206
        • Cassader M.
        • Ruiu G.
        • Gambino R.
        • Alemanno N.
        • Triolo G.
        • Pagano G.
        Apolipoprotein C and E in diabetic uraemic patients.
        Diabetes Nutrition Metab. 1989; 2: 33
        • Kissebah A.H.
        • Alfarsi S.
        • Evans D.J.
        • Adams P.W.
        Integrated regulation of very low density lipoprotein triglyceride and Apolpoprotein-B kinetics in noninsulin-dependent-diabetes mellitus.
        Diabetes. 1982; 31: 217
        • Taskinen M.R.
        • Beltz W.F.
        • Harper L.
        • Fields R.M.
        • Schonfeld G.
        • Grundy S.M.
        • Howard B.
        The effects of non-insulin-dependent diabetes mellitus on VLDL triglyceride and VLDL apoB metabolism: studies before and after sulfonylurea therapy.
        Diabetes. 1986; 35: 1286
        • Schonfeld G.
        • Birge C.
        • Miller J.P.
        • Kessler G.
        • Santiago J.
        Apolipoprotein B levels and altered lipoprotein composition in diabetes.
        Diabetes. 1974; 23: 827
        • Weisgraber K.H.
        • Innerarity T.L.
        • Mahley R.W.
        Role of the lipase residues of plasma lipoproteins in high affinity to cell surface receptors in human fibroblasts.
        J. Biol. Chem. 1978; 253: 9053
        • Steinbrecher U.P.
        • Wiztum J.L.
        Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism.
        Diabetes. 1984; 33: 130
        • Grundy S.M.
        HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
        N. Engl. J. Med. 1988; 319: 24
        • Brown M.S.
        • Goldstein J.L.
        Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic.
        J. Clin. Invest. 1983; 72: 743
        • East C.A.
        • Grundy S.M.
        • Bilheimer D.W.
        Preliminary report: treatment of type III hyperlipoproteinemia with mevinolin.
        Metabolism. 1986; 35: 97
        • Weintraub M.S.
        • Eisenberg S.
        • Breslow J.L.
        Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia.
        Eur. J. Clin. Invest. 1989; 19: 480
        • Kasim S.E.
        • LeBoeuf R.C.
        • Khilnani S.
        • Tallapaka L.
        • Dayananda D.
        • Jen K.L.C.
        Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase in hibitor in a hypertriglyceridemic animal model, Zucker obese rat.
        J. Lipid Res. 1992; 33: 1
        • Garg A.
        • Grundy S.M.
        Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
        N. Engl. J. Med. 1988; 2: 81
        • Kottke B.A.
        • Zinsmeister A.R.
        • Holmes D.R.
        • Kneller R.W.
        • Hallaway B.J.
        • Mao S.J.T.
        Apolipoproteins and coronary artery disease.
        in: Mayo Clin. Proc.61. 1986: 313
        • Stout R.W.
        Diabetes, atherosclerosis and aging.
        Diabetes Care. 1990; 13: 20